Wynn H, Ramesh M, Matowe W C, Wolowyk M W, Knaus E E
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
Drug Des Deliv. 1988 Nov;3(3):245-56.
Calcium channel antagonist activities of 1,2-dihydropyridines (10), including that (10d) isomeric with nifedipine, were determined using the muscarinic-receptor mediated Ca2+ dependent contraction of guinea pig ileal longitudinal smooth muscle. The effect of the 4-substituent (R) on potency was cyclohexyl and phenyl greater than 2-,3- or 4-trifluoromethyl(nitro)phenyl, although the differences in activity were small. The nature of the 4-substituent (alkyl, cycloalkyl, aryl), and the position (ortho, meta, para) of further substituents (CF3 or NO2) in the case of 4-phenyl substitution, were not major determinants of activity. The weaker calcium channel antagonist activity of these compounds, relative to nifedipine, is attributed to differences in conformation between the 1,2- and 1,4-dihydropyridine ring systems and the orientation of the 4-aryl substituent. In the synthetic work, the required 1,2-dihydropyridines (10), were synthesized by a route involving regiospecific ortho-directed reduction of the 1-oxide analogues (9) using borane. NMR spectrometric studies indicated that the 4-(2-trifluoromethyl) analogue (10a) exists as a single rotamer (10a'), whereas the 4-(2-nitrophenyl) analogue (10d) exists as a 10:3 mixture of rotamers (10d') and (10d") at 25 degrees C in CDCl3 solution.
使用豚鼠回肠纵行平滑肌中由毒蕈碱受体介导的Ca2+依赖性收缩,测定了1,2 - 二氢吡啶(10)的钙通道拮抗剂活性,其中包括与硝苯地平异构的化合物(10d)。4 - 取代基(R)对效力的影响为环己基和苯基大于2 -、3 - 或4 - 三氟甲基(硝基)苯基,尽管活性差异较小。4 - 取代基(烷基、环烷基、芳基)的性质,以及在4 - 苯基取代情况下进一步取代基(CF3或NO2)的位置(邻位、间位、对位),并非活性的主要决定因素。相对于硝苯地平,这些化合物较弱的钙通道拮抗剂活性归因于1,2 - 和1,4 - 二氢吡啶环系统之间的构象差异以及4 - 芳基取代基的取向。在合成工作中,所需的1,2 - 二氢吡啶(10)通过使用硼烷对1 - 氧化物类似物(9)进行区域特异性邻位导向还原的路线合成。核磁共振光谱研究表明,4 -(2 - 三氟甲基)类似物(10a)以单一旋转异构体(10a')形式存在,而4 -(2 - 硝基苯基)类似物(10d)在CDCl3溶液中于25℃时以旋转异构体(10d')和(10d")的10:3混合物形式存在。